

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-Wing
10th Floor, Sector-30A
Opp. Vashi Railway Station
Vashi, Navi Mumbai 400 703
Maharashtra, INDIA
Tel : +91-22-6794 2222
Fax : +91-22-6794 2111/333
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

February 11, 2016

To,
The Manager, Listing Dept.,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001.

Scrip Code: 524212

Dear Sir / Madam,

Sub.: Outcome of the Board Meeting held on 11 February, 2016

This is with reference to the above mentioned subject, we would like to inform you that the Board of Directors of the Company at its meeting held on 11 February, 2016 has inter alia, approved the following:


- a) Un-audited Financial Results of the Company for the Third quarter and nine months period ended 31 December,, 2015 alongwith Limited Review Report (from 1 October, 2015 to 31 December, 2015),

As per the provision of Regulation 33 of Listing Regulations we are enclosing herewith the Un-audited Financial Results of the Company for the Third quarter and nine months period ended 31 December, 2015.

We request you to take this information on your records & kindly acknowledge the receipt of the same.

Thanking you,

Yours truly,
For Wanbury Limited


Jitendra J. Gandhi
Company Secretary

Encl.: a/a.


Wanbury Limited

Regd. Office : BSEL Tech Park, B-Wing
10th Floor, Sector-30A
Opp. Vashi Railway Station
Vashi, Navi Mumbai 400 703
Maharashtra, INDIA
Tel : +91-22-6794 2222
Fax : +91-22-6794 2111/333
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

Wanbury Limited
Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2015

(₹ in Lacs)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Previous Period ended
		31-Dec-15	30-Sep-15	31-Dec-14	31-Dec-15	31-Dec-14	31-Mar-15
		Unaudited	Unaudited	Unaudited	Unaudited	Refer Note 10 Unaudited	Refer Note 9 Audited
1	Income from Operations						
	(a) Net Sales /Income from operations (net of excise duty)	9,991.38	10,561.72	12,520.08	32,450.91	36,222.16	24,673.25
	(b) Other operating income	130.20	92.27	79.25	299.33	287.30	319.08
	Total income from operations (net)	10,121.58	10,653.99	12,599.33	32,750.24	36,509.46	24,992.33
2	Expenses						
	(a) Cost of materials consumed	3,320.48	3,963.22	4,692.50	11,551.87	13,330.39	9,832.12
	(b) Purchase of stock-in-trade	947.17	967.75	980.89	2,979.68	3,902.87	1,812.56
	(c) Changes in inventories of finished goods, work-in-progress and stock in trade	568.91	(584.06)	108.64	(273.80)	(396.33)	360.73
	(d) Employee benefit expense	2,096.02	2,107.52	2,090.00	6,386.36	6,247.08	3,963.25
	(e) Depreciation and amortisation expense	232.72	223.05	212.22	661.87	1,024.38	480.42
	(f) Other expense	2,907.49	3,258.88	3,230.58	9,312.23	11,157.18	6,880.93
	Total expenses	10,072.79	9,936.36	11,314.83	30,618.21	35,265.57	23,330.01
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	48.79	717.63	1,284.50	2,132.03	1,243.89	1,662.32
4	Other income	38.25	19.28	63.69	93.10	210.00	648.40
5	Profit/(Loss) from ordinary activities before finance costs & exceptional items (3+4)	87.04	736.91	1,348.19	2,225.13	1,453.89	2,310.72
6	Finance costs	786.28	980.75	947.66	2,723.20	2,779.87	1,862.48
	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(699.24)	(243.84)	400.53	(498.07)	(1,325.98)	448.24
8	Exceptional items-Income(Expense)	-	-	-	-	(24,176.32)	-
9	Profit/(Loss) from ordinary activities before Tax (7-8)	(699.24)	(243.84)	400.53	(498.07)	(25,502.30)	448.24
10	Tax expense	-	-	58.62	-	175.87	127.48
11	Net Profit/(Loss) from ordinary activities after Tax (9-10)	(699.24)	(243.84)	341.91	(498.07)	(25,678.17)	320.76
12	Extraordinary items	-	-	-	-	-	-
13	Net Profit/(Loss) for the period (11-12)	(699.24)	(243.84)	341.91	(498.07)	(25,678.17)	320.76
14	Paid up Equity Share Capital (Face Value of ₹ 10 each)	1,996.93	1,996.93	1,996.93	1,996.93	1,996.93	1,996.93
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting period	N.A.	N.A.	N.A.	N.A.	N.A.	(21,262.66)
16	Earning per share (EPS)- not annualised (in ₹) :						
	Basic and Diluted	(3.50)	(1.22)	1.71	(2.49)	(128.59)	1.61



Wanbury Limited

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2015


Notes :-

- 1) The above financial results have been reviewed by the Audit Committee and have been taken on record at the meeting of the Board of Directors of the Company held on 11 February 2016.
- 2) The Company has only one segment of activity namely "Pharmaceuticals".
- 3) Erstwhile The Pharmaceutical Products of India Limited (PPIL) merged with the Company pursuant to the Scheme of Revival cum Merger (the Scheme) approved vide order dated 24 April 2007 by the Board for Industrial and Financial Reconstruction (BIFR) u/s 18 and other applicable provisions of the Sick Industrial Companies (Special Provisions) Act, 1985 (SICA) w.e.f. 1 April 2006, being the appointed date. Subsequently in response to a suit filed by one of the unsecured creditors of erstwhile PPIL, challenging the Scheme, the Hon'ble Supreme Court vide its order dated 16 May 2008, has set aside the above referred BIFR order and remitted the matter back to BIFR for considering afresh as per the provisions of SICA. The matter is now under BIFR's reconsideration. BIFR has directed IDBI Bank, which is an Operating Agency, to prepare the Draft Rehabilitation Scheme. In the meanwhile, the Company has sought legal opinion and has been advised to maintain status quo ante with respect to the merger under the said Scheme and that it should take further steps only on the basis of the fresh BIFR order. In view of the above, the Company has maintained a status quo. However, all actions taken by the Company pursuant to the sanctioned scheme shall remain subject to and without prejudice to the orders that may be passed by the BIFR while considering the case afresh pursuant to the directions of the Hon'ble Supreme Court in its order dated 16 May 2008.
- 4) Exim Bank has subscribed to 4,511 Preference Shares of Euro 1,000/- each of Wanbury Holding B. V., a subsidiary company pursuant to the Preference Share Subscription Agreement dated 7 December 2006. Pursuant to the said agreement, Exim Bank has exercised Put Option vide letter dated 8 November, 2011 and Company is required to pay USD 60 Lacs (Rs. 3,979.56 Lacs) to acquire aforesaid preference shares. Further, State Bank of India, London vide its letter dated 11 July 2012, has demanded repayment of Euro 32.60 Lacs (Rs. 2,363.53 Lacs) together with interest till the date of repayment from the Company in terms of Guarantee & Loan agreement dated 27 September 2007 vide which aforesaid credit facilities was granted to Cantabria Pharma S L, the step down subsidiary of the Company. Both the above mentioned dues being part of the CDR Scheme will be accounted upon arriving at mutually agreed terms of settlement with the respective parties.
- 5) The Company has initiated various measures, including restructuring of debts/business and infusion of funds etc. Consequently, in the opinion of the management, operations of the Company will continue without interruption. Hence, financial statements are prepared on a "going concern" basis.
- 6) Above includes remuneration to director for the quarter/nine months ended 31 December 2015 amounting to Rs. 12.65 Lacs and Rs. 37.12 Lacs respectively, as approved by the members at the Annual General Meeting of the Company held on 28 September 2015. Further, it is subject to the approval of the Central Government for which the Company has made application on 18 January 2016.
- 7) Depreciation for the period from 1 October 2014 to 31 March 2015 has been aligned to comply with the provisions of Schedule II of Companies Act, 2013 and accordingly an amount of Rs. 517.40 Lacs (net off tax Rs. Nil) in relation to assets where useful life has already expired on 1 October 2014, has been charged to the Retained Earnings. For the nine month period ended 31 December 2014, Exceptional item comprises of provision for permanent diminution in value of investments of Rs. 5,230.38 Lacs in all subsidiaries of the Company and Bravo Healthcare Limited, and provision for amount recoverable from the above entities amounting to Rs. 18,945.94 Lacs.
- 8) Previous financial year was from 1 October 2014 to 31 March 2015. However, in compliance with Companies Act, 2013, the current financial year will be from 1 April 2015 to 31 March 2016.
- 9) To Make it Comparative with current Nine Months year to date figure of 31 December 2015, Figure for the Nine months period ended 31 December 2014 are derived by aggregating published figures of quarter ended 30 June 2014, 30 September 2014 and 31 December 2014.
- 10) During the current quarter, State Bank of India (SBI) has informed about sale of its loan exposures on the Company to Edelweiss Asset Reconstruction Company Limited.
- 11) The figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.

Place : Mumbai

Date: 11 February 2016

For Wanbury Ltd.



K. Chandran

Vice Chairman

(DIN : 00005868)





KAPOOR & PAREKH ASSOCIATES
CHARTERED ACCOUNTANTS

Independent Auditors' Review Report

To,
The Board of Directors
Wanbury Limited
Navi Mumbai

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Wanbury Limited** ("the Company") for the quarter and nine months ended 31 December 2015 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 11 February 2016, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Attention is invited to:
 - a. Note No. 3 of the accompanied Statement regarding status of erstwhile PPIL matter with BIFR;
 - b. Note No. 5 of the accompanied Statement regarding accounts being prepared on "going concern" basis for the reasons stated therein; and
 - c. Note No. 6 of the accompanied Statement regarding director's remuneration being subject to the approval of the Central Government.

Our report is not qualified in respect of these matters.





KAPOOR & PAREKH ASSOCIATES
CHARTERED ACCOUNTANTS

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Accounting Standards and other accounting principles, practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kapoor & Parekh Associates
Chartered Accountants
ICAI FRN 104803W

Nikhil Patel
Partner

Membership No. 37032

Mumbai, 11 February 2016

